Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Shared cellular pathway drives neurodegeneration in rare childhood dementia and Alzheimer’s

Shared cellular pathway drives neurodegeneration in rare childhood dementia and Alzheimer’s

Nocturnal micro-awakenings linked to genetic risk of Alzheimer's disease

Nocturnal micro-awakenings linked to genetic risk of Alzheimer's disease

New multi-protein blood test accurately detects late-stage Alzheimer's disease

New multi-protein blood test accurately detects late-stage Alzheimer's disease

Comprehensive brain cell map opens new avenues for Alzheimer's therapies

Comprehensive brain cell map opens new avenues for Alzheimer's therapies

Faith-based screenings expand early dementia detection among African Americans

Faith-based screenings expand early dementia detection among African Americans

New USC center seeks answers to sex differences in aging

New USC center seeks answers to sex differences in aging

Disrupted RNA methylation pathway accelerates Alzheimer’s and Parkinson’s risks

Disrupted RNA methylation pathway accelerates Alzheimer’s and Parkinson’s risks

High-resolution scans reveal how depression affects hippocampal subfields

High-resolution scans reveal how depression affects hippocampal subfields

Study reveals treatment gaps for atypical Alzheimer's disease patients

Study reveals treatment gaps for atypical Alzheimer's disease patients

NIH funds Boston University center for Alzheimer's prevention studies

NIH funds Boston University center for Alzheimer's prevention studies

New metric detects early Alzheimer’s changes in brain's white matter

New metric detects early Alzheimer’s changes in brain's white matter

New study advances understanding of dementia after age 90

New study advances understanding of dementia after age 90

Exercise helps protect Hispanic adults from late life cognitive decline

Exercise helps protect Hispanic adults from late life cognitive decline

New 3D brain tissue model accelerates Alzheimer's drug development

New 3D brain tissue model accelerates Alzheimer's drug development

Study connects late-life psychosis to abnormal tau protein buildup

Study connects late-life psychosis to abnormal tau protein buildup

New AI model generates detailed maps of aging in brain regions

New AI model generates detailed maps of aging in brain regions

Discovery of calcium channel mechanism offers clues for brain disorder treatments

Discovery of calcium channel mechanism offers clues for brain disorder treatments

Overactive brain immune response linked to rare, severe genetic epilepsy

Overactive brain immune response linked to rare, severe genetic epilepsy

A closer look at Parkinson’s brains finds tau where standard tests saw little

A closer look at Parkinson’s brains finds tau where standard tests saw little

THC and CBD combination rapidly reduces advanced dementia agitation

THC and CBD combination rapidly reduces advanced dementia agitation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.